Management of Ulcerative Colitis: Putting Patients at the Centre - European Medical Journal

Management of Ulcerative Colitis: Putting Patients at the Centre

Download PDF
Iris Dotan1
Peter Irving,2 David T. Rubin3

Iris Dotan has been a consultant for and received grant support from AbbVie, Janssen, Takeda, Pfizer, Genentech, Rafa Laboratories, Protalix, Ferring, and Given Imaging. She has undertaken speaking and teaching engagements for AbbVie, Janssen, Takeda, Genentech, Ferring, Falk Pharma, Merck Sharp & Dohme, and Given Imaging. Peter Irving has received grant support from Merck Sharp & Dohme and Takeda, and has been a consultant for AbbVie, Merck Sharp & Dohme, Takeda, Warner Chilcott, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, Tillotts, and Symprove. He has taken part in Speaker Bureau activities for AbbVie, Falk Pharma, Ferring, Merck Sharp & Dohme, Takeda, Warner Chilcott, Johnson and Johnson, and Shire. David Rubin has been a consultant for AbbVie, Amgen, Celgene, Janssen, Pfizer, Prometheus, Takeda, and UCB. He has been a board member of the ACG Board of Trustees and is the VP of Cornerstones Health Incorporated, a non-profit medical education organisation.


Writing assistance was provided by Stephanie Gibson, PhD, Ashfield Healthcare Communications Ltd.


The publication of this article was funded by Takeda. The views and opinions expressed are those of the speakers and not necessarily of Takeda.

EMJ Gastroenterol. ;5[Suppl 6]:12-19. DOI/10.33590/emjgastroenterol/10313455.
ECCO, European Crohn's and Colitis Organisation

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The treatment landscape of ulcerative colitis (UC) is changing, with new treatment options becoming available and insights into disease management demonstrating the importance of a patient-centric approach. Induction and maintenance of long-term remission are important treatment goals. However, some of the current treatment options often have limited efficacy, which may be coupled with an unfavourable safety profile, such as an increased risk of infection. A multiphase approach to disease management, which includes induction and maintenance of remission through close monitoring, is a viable clinical strategy. Selecting an appropriate first-line therapy is a crucial part of this strategy, as options are sometimes limited for patients who have failed anti-tumour necrosis factor (TNF) therapy. The integrin antagonist, vedolizumab, has demonstrated effective induction and maintenance of clinical remission in both anti-TNF-naïve and anti-TNF-failure patients, with no increase in infection risks. Therefore, vedolizumab should be considered for inducing and maintaining remission as part of a patient-centric disease management programme. The development of simplified monitoring systems that provide an indication of endoscopic activity will also aid patients in taking charge of their disease management. In conclusion, putting our patients at the centre of a proactive model of disease management can help prevent complications in the long-term, and selecting suitable first-line therapies is an important step in this process.

Please view the full content in the PDF above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?